Budesonide and fluticasone propionate differentially affect the airway epithelial barrier

BACKGROUND: COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and FP differentially affect the mucosal barrier in response to viral infection and/or cigarette smoke. METHODS:...

Full description

Saved in:

Bibliographic Details
Published in:	Respir Res
Main Authors:	Heijink, I. H., Jonker, M. R., de Vries, M., van Oosterhout, A. J. M., Telenga, E., ten Hacken, N. H. T., Postma, D. S., van den Berge, M.
Format:	Artigo
Language:	Inglês
Published:	BioMed Central 2016
Subjects:	Research
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4704248/ https://ncbi.nlm.nih.gov/pubmed/26739349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-015-0318-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Budesonide and fluticasone propionate differentially affect the airway epithelial barrier

Similar Items